Sweeney K J, Sarcevic B, Sutherland R L, Musgrove E A
Cancer Research Program, Garvan Institute of Medical Research, St Vincent's Hospital, Sydney, NSW, Australia.
Oncogene. 1997 Mar 20;14(11):1329-40. doi: 10.1038/sj.onc.1200951.
To investigate the possibility of differing roles for cyclins D1 and D2 in breast epithelial cells, we examined the expression, cell cycle regulation and activity of these two G1 cyclins in both 184 normal breast epithelial cells and T-47D breast cancer cells. Synchronisation studies in 184 cells demonstrated that cyclin D1 and cyclin D2 were differentially regulated during G1, with cyclin D2 abundance increasing by 3.7-fold but only small changes in cyclin D1 abundance observed. The functional consequences of increased cyclin D2 expression were examined in T-47D cells, which express no detectable cyclin D2. Induced expression of cyclin D2 resulted in increases in cyclin E expression, pRB phosphorylation and the percentage of cells in S-phase, while constitutive expression resulted in a consistent trend toward reduced dependence on serum for continued proliferation. Thus, cyclin D2 is a positive regulator of G1 progression in breast cells analogous to the well-documented effects of cyclin D1. Indeed, equimolar concentrations of inducible cyclin D1 and D2 resulted in quantitatively similar cell cycle effects. Marked divergence was found, however, in the CDKs activated by the two cyclins in breast epithelial cells. Cyclin D2 complexes contained a higher Cdk2/Cdk4 ratio than cyclin D1 complexes. The cyclin D2-associated kinase activity was largely inhibited by Cdk2-specific inhibitors and could phosphorylate histone H1, a substrate for Cdk2 but not for Cdk4 and Cdk6. Therefore, cyclin D2 preferentially activated Cdk2 in breast epithelial cells. In contrast, Cdk4 and Cdk6 were predominantly responsible for cyclin D1-associated kinase activity as previously reported. Thus, although cyclins D1 and D2 elicited similar effects on breast epithelial cell cycle progression they appeared to achieve this end via activation of different CDKs. This is the first evidence of cyclin D2 activating Cdk2 in mammalian cells thus providing further evidence that D-type cyclins are not necessarily redundant.
为了研究细胞周期蛋白D1和D2在乳腺上皮细胞中发挥不同作用的可能性,我们检测了这两种G1期细胞周期蛋白在184个正常乳腺上皮细胞和T-47D乳腺癌细胞中的表达、细胞周期调控及活性。对184个细胞进行的同步化研究表明,细胞周期蛋白D1和D2在G1期受到不同调控,细胞周期蛋白D2的丰度增加了3.7倍,而细胞周期蛋白D1的丰度仅有微小变化。在不表达可检测到的细胞周期蛋白D2的T-47D细胞中,检测了细胞周期蛋白D2表达增加的功能后果。诱导表达细胞周期蛋白D2导致细胞周期蛋白E表达增加、pRB磷酸化以及S期细胞百分比增加,而组成型表达导致细胞对血清持续增殖的依赖性呈持续降低趋势。因此,细胞周期蛋白D2是乳腺细胞中G1期进程的正向调节因子,类似于细胞周期蛋白D1的已充分证明的作用。实际上,等摩尔浓度的可诱导细胞周期蛋白D1和D2导致了在数量上相似的细胞周期效应。然而,在乳腺上皮细胞中,发现由这两种细胞周期蛋白激活的CDK存在明显差异。细胞周期蛋白D2复合物中Cdk2/Cdk4的比例高于细胞周期蛋白D1复合物。细胞周期蛋白D2相关的激酶活性在很大程度上受到Cdk2特异性抑制剂的抑制,并且能够磷酸化组蛋白H1,组蛋白H1是Cdk2的底物而非Cdk4和Cdk6的底物。因此,在乳腺上皮细胞中,细胞周期蛋白D2优先激活Cdk2。相比之下,如先前报道,Cdk4和Cdk6主要负责细胞周期蛋白D1相关的激酶活性。因此,尽管细胞周期蛋白D1和D2对乳腺上皮细胞周期进程产生了相似的影响,但它们似乎是通过激活不同的CDK来实现这一目的。这是细胞周期蛋白D2在哺乳动物细胞中激活Cdk2的首个证据,从而进一步证明D型细胞周期蛋白不一定是冗余的。